Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

Company Overview

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) is a clinical‐stage biopharmaceutical company focused on developing precision medicines for rare genetic diseases caused by nonsense mutations. Its lead candidate, ELX-02, is a novel small molecule designed to enable ribosomal read-through of premature stop codons and restore production of full-length, functional proteins. The company’s initial therapeutic targets include cystic fibrosis and cystinosis, with ELX-02 advancing through Phase 2 clinical studies in cystic fibrosis and Phase 1/2 trials in cystinosis.

In addition to ELX-02, Eloxx is advancing second-generation read-through compounds in its discovery pipeline to broaden treatment opportunities for patients with other nonsense mutation-driven disorders. The company’s research and development efforts leverage proprietary chemistry to optimize efficacy and safety profiles, and it has established clinical sites across North America and Europe to support multi-regional trials. Eloxx aims to address a high unmet medical need by providing targeted therapies where few or no approved options exist.

Founded in 2016 and incorporated in Delaware, Eloxx Pharmaceuticals is headquartered in Mamaroneck, New York. The company’s management team includes seasoned biotechnology executives with deep expertise in rare disease drug development, clinical operations and regulatory affairs. Eloxx is committed to advancing its pipeline through clinical milestones and to forging strategic collaborations that can accelerate development timelines and expand patient access worldwide.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.75
• Volume: 81,393 shs
• Average Volume: 5,306 shs
• Market Capitalization: $314.30
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ELOX Stock Analysis - Frequently Asked Questions

How have ELOX shares performed this year?

Eloxx Pharmaceuticals' stock was trading at $0.0001 at the beginning of 2025. Since then, ELOX shares have increased by 0.0% and is now trading at $0.0001.

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) released its quarterly earnings results on Monday, April, 3rd. The company reported ($2.92) earnings per share for the quarter, beating the consensus estimate of ($2.97) by $0.05.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eloxx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eloxx Pharmaceuticals investors own include Tesla (TSLA), ADMA Biologics (ADMA), Adverum Biotechnologies (ADVM), Assertio (ASRT), Fulcrum Therapeutics (FULC), Acasti Pharma (ACST) and Akebia Therapeutics (AKBA).

Company Calendar

• Last Earnings: 4/03/2023
• Today: 10/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELOX
• CIK: 1035354
• Web: www.eloxxpharma.com
• Phone: (781) 577-5300
• Fax: 908-864-4440
• Employees: 30
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,143,000
• Free Float: 2,508,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -1,629.93